Johnson & Johnson (J&J) has announced that a US Food and Drug Administration (FDA) panel of experts has recommended Darzalex ...

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 ...

This sounds entirely obvious but failure to translate this insight into more innovative patient support contributes to the ...

Bristol Myers Squibb (BMS) has announced that its PD-1 immune checkpoint inhibitor Opdivo (nivolumab) has been approved by ...

Results presented at this year’s American Thoracic Society International Conference showed that the trials met their primary ...

Join us on an adventure Alex Legg is one of 15 speakers at Adventures In Pharma on 1 July in London. Join him there to ...

The agreement between BioNTech’s subsidiary BioNTech UK and the UK government is focused on accelerating clinical trials for ...

Olaparib tablets, marketed under the brand name Lynparza, are already available on the NHS for certain breast cancer ...

The struggle to make clinical trials easier to conduct and more attractive to patients while understanding the impact of ...

Science communication, together with creativity, ensures that information is both accurate and accessible. In order to ...

Medscape Oncology is making a powerful impact at ASCO 2025, bringing seven high-impact symposia, new research insights, and ...

Regeneron Pharmaceuticals has announced that it will be acquiring human genetics and biotechnology company 23andMe for $256m.